# Autotransfusion Devices Market > Autotransfusion Devices Market Research Report: Size, Share, Trend Analysis By Product Type (On-pump Transfusion Device and Off-pump Transfusion Device), By End-user (Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.2% - **2024:** $ 0.4 Billion - **2025:** $ 0.42 Billion - **2035:** $ 0.7 Billion - **Key Players:** Haemonetics Corporation (US), Terumo Corporation (JP), Medtronic plc (IE), LivaNova PLC (GB), Fresenius Kabi AG (DE), Stryker Corporation (US), B. Braun Melsungen AG (DE), C.R. Bard, Inc. (US) **Report ID:** MRFR/HC/20568-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/autotransfusion-devices-market-22168 --- ## Market Summary ## **Global Autotransfusion Devices Market Overview** Autotransfusion Devices Market Size was valued at USD 0.3 Billion in 2023. The autotransfusion devices market industry is projected to grow from USD 0.4 Billion in 2024 to USD 0.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.20% during the forecast period (2024 - 2032). The increasing need for safety and quality in medical practice, availability of implantable systems with advantages, improved health care, faster diagnosis of diseases, and increasing anemia are the key market drivers driving the global market for autotransfusion devices. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Autotransfusion Devices Market Trends** With the growing incidence of cardiovascular disease becoming a major factor, the market for autotransfusion devices has been forecast to grow considerably in the next few years at a high market CAGR. Cardiovascular Diseases (CVDs) are a set of conditions that involve the heart as well as blood vessels. Automation is the primary reason behind the trend of substituting patient blood transfusions with allogeneic transfusions. The act of allogeneic blood transfusion implies that blood is donated externally, while autotransfusion optimizes the usage of a patient's blood to induce positive changes and prevent the risks and complications associated with transfusions. For example, the AHA released a report last year stating the manner of CVDs, and this caused about 85% of deaths that year. At present, about 9 million deaths result from the disease every year around the world, the top cause of death globally. Therefore, this type of equipment is required equally as the number of people living with heart disease is increasing. There is expected growth in the autotransfusion device market because of the increasing demand for blood preservation. The act of refraining from using allogeneic blood transfusions before and after surgery, with the goal of improving patient outcomes and protecting their rights, is referred to as "blood conservation." Autotransfusion devices can be used during surgical procedures to reduce blood loss and improve patient outcomes. An example would be a report in June 2023 from the Geneva-based intergovernmental World Health Organization (WHO) which indicated that 73% of the reporting countries, or 125 out of 171 countries, had a national blood policy. In total, explicit laws governing the quality and safety of blood transfusions are in place in 66% of the 171 reporting countries, which amounts to 113 countries. This consists of 79% of wealthy nations, 63% of average-earning nations, and 39% of impoverished nations. The demand for autotransfusion devices is increasing due to the rising requirement for blood preservation. In addition, there is no longer a chance of isosensitization; autologous blood ensures better oxygen transfer and higher activity of coagulation factors, pretransfusion examinations are avoided, surgery doesn't need to be postponed due to blood scarcity, homologous blood consumption is decreased, economy is improved, and religious objections to the transfusion of homologous blood are removed. Autotransfusion carries no drawbacks. Before a scheduled procedure, patients had blood drawn for autotransfusion; often, two separate blood draws were conducted in quick succession. There were no complications that put the patient's health in danger. The remarkable rise in the acceptance of autotransfusion can be attributed to the global spread of the AIDS pandemic and the public's growing critical understanding of medical operations in general and blood transfusions in particular. Thus, driving the autotransfusion devices market revenue. ## **Autotransfusion Devices Market Segment Insights** ### **Autotransfusion Devices Product Type Insights** The Autotransfusion Devices Market segmentation, based on product type, includes On-pump Transfusion Device and Off-pump Transfusion Device. In 2023, the off-pump transfusion device segment dominated the market. The flexibility of mechanical control and the ability to prevent blood loss throughout the transfusion process make pump transfusion effective for post-pump transfusions and surgery. Substantial reductions in background morbidity and mortality rates, especially in high-risk patients, are major trends in this field. ### **Autotransfusion Devices End-user Insights** The Autotransfusion Devices Market segmentation, based on end-user, includes Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers. The hospitals category generated the most income in 2023. This is due to the fact that hospitals have specialized departments that require blood transfusions. Consequently, there is a need for more automated devices to meet the [dialysis](../../../reports/kidney-dialysis-equipment-market-6302) needs of patients with unique characteristics. In addition, guidelines from the American Blood Bank Association, which state that blood must be drawn again after four hours for washout, are driving global demand for automated devices. **Figure 1: Autotransfusion Devices Market, by End-user, 2023 & 2032 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **Autotransfusion Devices Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American autotransfusion devices market area will dominate this market. This is due to the increasing emphasis on autologous blood transfusions in orthopedic and cardiac [critical care](../../../reports/mea-critical-care-equipment-market-2751) and the established infrastructure that has helped the local market, in addition to the increasing number of orthopedic heart failure patients and the elderly population. The market is expected to increase, increasing the demand for organ transplantation Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 2: AUTOTRANSFUSION DEVICES MARKET SHARE BY REGION 2023 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review Europe autotransfusion devices market accounts for the second-largest market share attributed to the growth of the regional market, driven by increasing emphasis on autotransfusion in critical cardiovascular procedures and built-in Other factors expected to drive market expansion are increasing number of patients with osteoporosis and cardiovascular disease and an aging population that increases the chances of organ transplantation. Further, the German autotransfusion devices market held the largest market share, and the UK autotransfusion devices market was the fastest growing market in the European region. The Asia-Pacific Autotransfusion Devices Market is expected to grow at the fastest CAGR from 2024 to 2032, driven by the entry of new companies into the market and the rising awareness of cell salvage technologies. Significant growth prospects are also expected to be presented in the region by the rapidly increasing number of surgical procedures and the building of healthcare infrastructure in China and India. Moreover, China’s autotransfusion devices market held the largest market share, and the Indian autotransfusion devices market was the fastest growing market in the Asia-Pacific region. ## **Autotransfusion Devices Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the autotransfusion devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the autotransfusion devices industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global autotransfusion devices industry to benefit clients and increase the market sector. In recent years, the autotransfusion devices industry has offered some of the most significant advantages to medicine. Major players in the autotransfusion devices market are attempting to increase market demand by investing in research and development operations, including Terumo Corporation, Fresenius Kabi AG, Haemonetics Corporation, Medtronic, Stryker, LivaNova PLC, Atrium Medical Technologies, and Advancis Surgical. Healthcare provider Haemonetics Corp (Haemonetics) provides software and systems for blood management. The company offers information management software, integrated devices, and clinical outcome improvement consulting services. Additionally, it provides a whole variety of blood supply chain solutions, from hospitals to plasma and blood collectors. Haemonetics established a manufacturing center of excellence for the development of auto-transfusion systems in Clinton, Pennsylvania, in June 2022. The company's product line is anticipated to grow as a result of the specially constructed facility. Fresenius Kabi AG (Fresenius Kabi) is a subsidiary of Fresenius SE & Co KGaA that is involved in the development, production, and marketing of medical equipment and pharmaceuticals. Its product line consists of medical devices, infusion therapy items, injectable medications, and clinical nutrition products. The organization provides therapeutic competence in the following areas: pediatrics, maldigestion or malabsorption, liver insufficiency, renal insufficiency, anesthesia, critical sickness, and blood volume substitution. With the goal of providing cutting-edge new pharmacy technology to American hospitals and health systems, Fresenius SE & Co. KGaA announced in November 2021 that it would be collaborating with Omnicell, Inc. ### **Key companies in the autotransfusion devices market include** ### **Autotransfusion Devices Industry Developments** **March 2023: **The US FDA (Food and Drug Administration) has given 510(k) certification to Haemonetics Corporation for the next-generation software for the Cell Saver Elite+ Autotransfusion System, meaning it is now prepared for full market distribution. This offers crucial innovations to streamline processes, leading to higher output and an improved user experience. **September 2022: **The autotransfusion medical device, Same by i-SEP, was given CE marking, and the company started marketing it. Together with the patient's red blood cells, it is one of the intraoperative autotransfusion technologies that can preserve platelets. **October 2021: **Specialty Care Inc. was purchased by US-based Morgan Stanley Infrastructure Inc., a renowned infrastructure and investment management company, for an unknown sum. Being Morgan Stanley Infrastructures's first healthcare investment, the transaction was made with the company's growth and patient care outcomes in mind. A US-based supplier of autotransfusion system services is Specialty Care Inc. ## **Autotransfusion Devices Market Segmentation** ### **Autotransfusion Devices Product Type Outlook** ### **Autotransfusion Devices End-user Outlook** ### **Autotransfusion Devices Regional Outlook** ## Market Drivers ### Technological Innovations Technological innovations in the field of autotransfusion devices are propelling the growth of the Autotransfusion Devices Market. Recent advancements have led to the development of more efficient and user-friendly devices, enhancing their functionality and reliability. Innovations such as automated blood collection systems and improved filtration techniques have made autotransfusion devices more effective in various surgical settings. Market data suggests that the introduction of these advanced technologies is likely to increase adoption rates among healthcare providers. Furthermore, the integration of digital technologies, such as real-time monitoring and data analytics, is expected to enhance the overall performance of autotransfusion devices. As healthcare facilities seek to improve patient outcomes and streamline operations, the demand for technologically advanced autotransfusion solutions is anticipated to rise. ### Increasing Surgical Procedures The rise in surgical procedures across various medical specialties is a primary driver for the Autotransfusion Devices Market. As surgical interventions become more common, the need for effective blood management solutions intensifies. In recent years, the number of surgeries performed has shown a steady increase, with estimates suggesting that millions of procedures are conducted annually. This trend is likely to continue, as advancements in surgical techniques and technologies facilitate more complex operations. Consequently, the demand for autotransfusion devices, which allow for the collection and reinfusion of a patient's own blood, is expected to grow. This growth is further supported by the increasing awareness of the benefits of autotransfusion, including reduced risk of transfusion-related complications and improved patient outcomes. ### Rising Incidence of Trauma Cases The escalating incidence of trauma cases, including accidents and injuries, significantly influences the Autotransfusion Devices Market. Trauma cases often require immediate surgical intervention, leading to substantial blood loss. Autotransfusion devices play a crucial role in managing this blood loss by enabling the rapid collection and reinfusion of a patient's own blood. Data indicates that trauma-related injuries account for a considerable percentage of emergency room visits and surgical procedures. As the global population continues to grow and urbanization increases, the frequency of [trauma](https://www.marketresearchfuture.com/reports/trauma-care-centers-market-27928) cases is likely to rise, thereby driving the demand for autotransfusion devices. This trend underscores the importance of effective blood management solutions in trauma care, positioning autotransfusion devices as essential tools in modern medical practice. ### Regulatory Support and Guidelines Regulatory support and guidelines play a pivotal role in shaping the Autotransfusion Devices Market. Various health authorities and organizations are establishing standards and protocols that encourage the use of autotransfusion devices in clinical practice. These regulations aim to ensure patient safety and promote best practices in blood management. As healthcare facilities strive to comply with these guidelines, the demand for autotransfusion devices is expected to rise. Additionally, regulatory bodies are increasingly recognizing the importance of autotransfusion in reducing reliance on donor blood, which can be scarce in certain regions. This recognition is likely to foster a more favorable environment for the development and adoption of autotransfusion technologies, ultimately contributing to market growth. ### Growing Awareness of Blood Conservation The growing awareness of blood conservation strategies among healthcare professionals and patients is a significant driver for the Autotransfusion Devices Market. As the risks associated with allogeneic blood transfusions become more widely recognized, there is an increasing emphasis on utilizing a patient's own blood whenever possible. This shift in perspective is fostering a greater acceptance of autotransfusion devices as a viable alternative to traditional blood transfusions. Educational initiatives and guidelines from medical organizations are further promoting the benefits of autotransfusion, including reduced transfusion-related complications and improved recovery times. Market analysis indicates that this heightened awareness is likely to lead to increased adoption of autotransfusion devices in surgical and trauma settings, thereby expanding the market. ## Future Outlook The Autotransfusion Devices Market is projected to grow at a 5.2% CAGR from 2025 to 2035, driven by technological advancements, increasing surgical procedures, and rising awareness of blood conservation. **New opportunities:** - Development of portable autotransfusion devices for emergency medical services. Integration of AI for enhanced blood recovery efficiency. Expansion into emerging markets with tailored product offerings. By 2035, the Autotransfusion Devices Market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product Type: On-pump Transfusion Device (Largest) vs. Off-pump Transfusion Device (Fastest-Growing) The Autotransfusion Devices Market exhibits a split in market share between on-pump and off-pump transfusion devices, wherein on-pump transfusion devices dominate the landscape due to their established presence and widespread acceptance in surgical environments. These devices have been recognized for their efficacy in retrieving and reinfusing blood, leading to their predominant share in hospitals and surgical centers. Conversely, off-pump transfusion devices are gaining momentum as they present an alternative approach, appealing to surgical teams looking to minimize blood loss without the support of a pump, thus capturing a smaller yet rapidly growing segment of the market. Transfusion Devices: On-pump (Dominant) vs. Off-pump (Emerging) On-pump transfusion devices are characterized by their operational efficiency and reliability during surgical procedures, routinely utilized in open-heart surgeries and lengthy medical interventions. Their ability to manage larger volumes of blood efficiently makes them a staple in blood management strategies, thus cementing their dominant position in the market. On the other hand, off-pump transfusion devices, while still emerging, are engineered to cater to less invasive procedures, appealing to healthcare providers focused on innovation and patient-centric methods. This shift speaks to a broader trend towards less invasive surgical techniques, indicating a proactive approach to patient recovery and care, setting the stage for a progressively influential market position. ### By End-user: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the Autotransfusion Devices Market, hospitals represent the largest end-user segment, holding a significant portion of the market share. This dominance is attributed to the increasing number of surgical procedures and the demand for safe blood management practices in these facilities. Additionally, the established infrastructure within hospitals facilitates the integration of advanced autotransfusion devices, catering to varied surgical needs and enhancing patient outcomes. Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging) Hospitals are characterized by their advanced technology and vast resources, making them the dominant force in the autotransfusion devices market. These facilities benefit from a higher patient volume, requiring efficient blood management solutions during surgical interventions. On the other hand, ambulatory surgical centers are emerging rapidly in this market due to the shift towards outpatient procedures. Their growth is driven by the rising preference for same-day discharge surgeries and the cost-effectiveness of these centers, which are increasingly adopting advanced autotransfusion technologies to enhance patient satisfaction and operational efficiency. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America is the largest market for autotransfusion devices, holding approximately 45% of the global market share. The growth is driven by increasing surgical procedures, advancements in medical technology, and a strong focus on patient safety. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring high standards for device efficacy and safety. The United States is the primary contributor, with significant investments in healthcare infrastructure and technology. Key players such as Haemonetics Corporation and Medtronic plc dominate the landscape, fostering competition and innovation. The presence of established healthcare systems and a growing elderly population also contribute to the rising demand for autotransfusion devices. ### Europe : Emerging Market with Regulations Europe is the second-largest market for autotransfusion devices, accounting for around 30% of the global share. The region benefits from stringent regulatory frameworks that ensure high-quality medical devices, driving demand for advanced autotransfusion solutions. Countries like Germany and the UK are at the forefront, with increasing investments in healthcare technology and a growing emphasis on minimally invasive surgical procedures. Germany leads the market, supported by a robust healthcare system and a high prevalence of surgical interventions. The competitive landscape features key players such as Fresenius Kabi AG and B. Braun Melsungen AG. The European Medicines Agency plays a crucial role in regulating these devices, ensuring safety and efficacy, which further enhances market growth. ### Asia-Pacific : Rapid Growth and Adoption Asia-Pacific is witnessing rapid growth in the autotransfusion devices market, driven by increasing healthcare expenditure and a rising number of surgical procedures. The region holds approximately 20% of the global market share, with countries like Japan and China leading the charge. The growing awareness of blood conservation techniques and advancements in medical technology are key demand drivers. Japan is a significant player, with a strong focus on innovation and quality in healthcare. The competitive landscape includes companies like Terumo Corporation, which is expanding its product offerings. The region's diverse healthcare needs and increasing investments in medical infrastructure are expected to propel market growth further, making it a vital area for future developments. ### Middle East and Africa : Untapped Potential in Healthcare The Middle East and Africa region is gradually emerging in the autotransfusion devices market, currently holding about 5% of the global share. The growth is primarily driven by increasing healthcare investments and a rising number of surgical procedures. Countries like South Africa and the UAE are focusing on enhancing their healthcare systems, which is expected to boost demand for advanced medical devices. South Africa is leading the market, supported by government initiatives aimed at improving healthcare access. The competitive landscape is still developing, with opportunities for key players to establish a foothold. As healthcare infrastructure improves, the demand for autotransfusion devices is anticipated to grow, presenting significant opportunities for market entrants. ## Competitive Benchmarking The Autotransfusion Devices Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing emphasis on patient safety and cost-effectiveness. Key players such as Haemonetics Corporation (US), Terumo Corporation (JP), and Medtronic plc (IE) are strategically positioned to leverage innovation and expand their market presence. Haemonetics Corporation (US) focuses on enhancing its product portfolio through continuous innovation, while Terumo Corporation (JP) emphasizes regional expansion and partnerships to strengthen its foothold in emerging markets. Medtronic plc (IE) is actively pursuing digital transformation initiatives, which collectively shape a competitive environment that is increasingly reliant on technological differentiation and strategic collaborations.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency and responsiveness to market demands. The competitive structure of the Autotransfusion Devices Market appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and services, fostering innovation and competition among the leading firms. In August Haemonetics Corporation (US) announced the launch of a new autotransfusion device designed to improve blood recovery efficiency during surgical procedures. This strategic move is significant as it not only enhances the company's product offerings but also aligns with the growing demand for advanced medical technologies that prioritize patient outcomes. The introduction of this device is likely to strengthen Haemonetics' market position and attract new customers seeking innovative solutions. In September Terumo Corporation (JP) entered into a strategic partnership with a leading healthcare provider in Asia to enhance the distribution of its autotransfusion devices. This collaboration is indicative of Terumo's commitment to expanding its market reach and improving accessibility to its products in key regions. Such partnerships are essential for navigating the complexities of local markets and ensuring that innovative solutions are readily available to healthcare professionals. In October Medtronic plc (IE) unveiled a new digital platform that integrates artificial intelligence with its autotransfusion devices, aimed at optimizing surgical workflows. This development underscores Medtronic's focus on digitalization and the integration of advanced technologies into its product offerings. By leveraging AI, the company is likely to enhance operational efficiencies and improve patient outcomes, positioning itself as a leader in the evolving landscape of medical technology. As of October current trends in the Autotransfusion Devices Market indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, moving away from traditional price-based competition. Companies that prioritize innovation and adaptability are likely to thrive in this evolving market. ## Recent News & Developments **March 2023: **The US FDA (Food and Drug Administration) has given 510(k) certification to Haemonetics Corporation for the next-generation software for the Cell Saver Elite+ Autotransfusion System, meaning it is now prepared for full market distribution. This offers crucial innovations to streamline processes, leading to higher output and an improved user experience. **September 2022: **The autotransfusion medical device, Same by i-SEP, was given CE marking, and the company started marketing it. Together with the patient's red blood cells, it is one of the intraoperative autotransfusion technologies that can preserve platelets. **October 2021: **Specialty Care Inc. was purchased by US-based Morgan Stanley Infrastructure Inc., a renowned infrastructure and investment management company, for an unknown sum. Being Morgan Stanley Infrastructures's first healthcare investment, the transaction was made with the company's growth and patient care outcomes in mind. A US-based supplier of autotransfusion system services is Specialty Care Inc. ## Report Scope | MARKET SIZE 2024 | 0.4(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 0.4208(USD Billion) | | MARKET SIZE 2035 | 0.6988(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Haemonetics Corporation (US), Terumo Corporation (JP), Medtronic plc (IE), LivaNova PLC (GB), Fresenius Kabi AG (DE), Stryker Corporation (US), B. Braun Melsungen AG (DE), C.R. Bard, Inc. (US) | | Segments Covered | Product Type, End-user, Region | | Key Market Opportunities | Integration of advanced automation and artificial intelligence in Autotransfusion Devices Market enhances efficiency and patient outcomes. | | Key Market Dynamics | Rising demand for autotransfusion devices driven by advancements in surgical procedures and increasing patient safety awareness. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Autotransfusion Devices Market by 2035?** A: The projected market valuation for the Autotransfusion Devices Market by 2035 is 0.6988 USD Billion. **Q: What was the market valuation of the Autotransfusion Devices Market in 2024?** A: The overall market valuation of the Autotransfusion Devices Market was 0.4 USD Billion in 2024. **Q: What is the expected CAGR for the Autotransfusion Devices Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Autotransfusion Devices Market during the forecast period 2025 - 2035 is 5.2%. **Q: Which product types are included in the Autotransfusion Devices Market?** A: The Autotransfusion Devices Market includes On-pump Transfusion Devices and Off-pump Transfusion Devices. **Q: What were the market values for On-pump and Off-pump Transfusion Devices in 2024?** A: In 2024, both On-pump and Off-pump Transfusion Devices had market values of 0.2 USD Billion. **Q: What is the projected market value for On-pump and Off-pump Transfusion Devices by 2035?** A: By 2035, the projected market value for both On-pump and Off-pump Transfusion Devices is expected to reach 0.3494 USD Billion. **Q: Who are the key players in the Autotransfusion Devices Market?** A: Key players in the Autotransfusion Devices Market include Haemonetics Corporation, Terumo Corporation, and Medtronic plc, among others. **Q: What are the primary end-user segments for Autotransfusion Devices?** A: The primary end-user segments for Autotransfusion Devices include Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers. **Q: What were the market values for Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers in 2024?** A: In 2024, the market values were 0.16 USD Billion for Hospitals, 0.12 USD Billion for Ambulatory Surgical Centers, and 0.12 USD Billion for Cardiac Research Centers. **Q: What is the projected market value for Hospitals, Ambulatory Surgical Centers, and Cardiac Research Centers by 2035?** A: By 2035, the projected market values are 0.28 USD Billion for Hospitals, 0.21 USD Billion for Ambulatory Surgical Centers, and 0.19 USD Billion for Cardiac Research Centers. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/autotransfusion-devices-market-22168*